Th9 cells: A novel CD4 T-cell subset in the immune war against cancer

Cancer Research

Volumn 75, Issue 3, 2015, Pages 475-479

  Végran, Frédérique ^a,b   Apetoh, Lionel ^a,b,c   Ghiringhelli, Franҫois ^a,b,c  

^a boulevard Jeanne d'Arc   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c CENTRE GEORGES FRANÇOIS LECLERC   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR6; GAMMA INTERFERON; INTERLEUKIN 21; INTERLEUKIN 9; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; INTERLEUKIN DERIVATIVE;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CELL POLARITY; CELL THERAPY; CELL TRANSDIFFERENTIATION; CYTOKINE RELEASE; DISEASE ASSOCIATION; HUMAN; LYMPHOCYTE DIFFERENTIATION; MOLECULAR PATHOLOGY; NONHUMAN; POLARIZATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TH9 CELL; TRANSCRIPTION REGULATION; TUMOR IMMUNITY; ANIMAL; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CYTOLOGY; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HELPER CELL; IMMUNOLOGY; MOUSE; NEOPLASM; T LYMPHOCYTE;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; GENE EXPRESSION PROFILING; HUMANS; INTERLEUKIN-9; INTERLEUKINS; MICE; NEOPLASMS; T-LYMPHOCYTES; T-LYMPHOCYTES, HELPER-INDUCER; TRANSCRIPTION, GENETIC;

EID: 84922205856     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-2748     Document Type: Review

References (37)

1. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8.
2. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348-57.
3. Traves PG, Luque A, Hortelano S. Macrophages, inflammation, and tumor suppressors: ARF, a new player in the game. Mediators Inflam 2012;2012:568783.
4. Menetrier-Caux C, Faget J, Biota C, Gobert M, Blay JY, Caux C. Innate immune recognition of breast tumor cells mediates CCL22 secretion favoring Treg recruitment within tumor environment. Oncoimmunology 2012;1:759-61.
5. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013;39:782-95.
6. Du JW, Xu KY, Fang LY, Qi XL. Interleukin-17, produced by lymphocytes, promotes tumor growth and angiogenesis in a mouse model of breast cancer. Mol Med Rep 2012;6:1099-102.
7. Chalmin F, Mignot G, Bruchard M, Chevriaux A, Végran F, Hichami A, et al. Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression. Immunity 2012;36:362-73.
8. Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, et al. T helper 17 cells promote cytotoxic T-cell activation in tumor immunity. Immunity 2009;31:787-98.
9. + Foxp3(-) effector T cells. Nat Immunol 2008;9:1347-55.
10. Veldhoen M, Uyttenhove C, van Snick J, Helmby H, Westendorf A, Buer J, et al. Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol 2008;9:1341-6.
11. Jager A, Dardalhon V, Sobel RA, Bettelli E, Kuchroo VK. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J Immunol 2009;183:7169-77.
12. Chang HC, Sehra S, Goswami R, Yao W, Yu Q, Stritesky GL, et al. The transcription factor PU.1 is required for the development of IL9-producing T cells and allergic in flammation. Nat Immunol 2010;11:527-34.
13. Purwar R, Schlapbach C, Xiao S, Kang HS, Elyaman W, Jiang X, et al. Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med 2012;18:1248-53.
14. Lu Y, Hong S, Li H, Park J, Hong B, Wang L, et al. Th9 cells promote antitumor immune responses in vivo. J Clin Invest 2012;122:4160-71.
15. Vegran F, Berger H, Boidot R, Mignot G, Bruchard M, Dosset M, et al. The transcription factor IRF1 dictates the IL21-dependent anticancer functions of TH9 cells. Nat Immunol 2014;15:758-66.
16. Murugaiyan G, Beynon V, Pires Da Cunha A, Joller N, Weiner HL. B. IFN-g limits Th9-mediated autoimmune inflammation through dendritic cell modulation of IL27. J Immunol 2012;189:5277-83.
17. LiaoW, Spolski R, Li P, Du N,West EE, Ren M, et al. Opposing actions of IL2 and IL21 on Th9 differentiation correlate with their differential regulation of BCL6 expression. Proc Natl Acad Sci U S A 2014;111:3508-13.
18. Angkasekwinai P, Chang SH, Thapa M, Watarai H, Dong C. Regulation of IL9 expression by IL25 signaling. Nat Immunol 2010;11:250-6.
19. Elyaman W, Bassil R, Bradshaw EM, Orent W, Lahoud Y, Zhu B, et al. Notch receptors and Smad3 signaling cooperate in the induction of interleukin-9-producing T cells. Immunity 2012;36:623-34.
20. Xiao X, Balasubramanian S, Liu W, Chu X, Wang H, Taparowsky EJ, et al. OX40 signaling favors the induction of T(H)9 cells and airway inflammation. Nat Immunol 2012;13:981-90.
21. Goswami R, Jabeen R, Yagi R, Pham D, Zhu J, Goenka S, et al. STAT6-dependent regulation of Th9 development. J Immunol 2012;188:968-75.
22. Chang HC, Zhang S, Thieu VT, Slee RB, Bruns HA, Laribee RN, et al. PU.1 expression delineates heterogeneity in primary Th2 cells. Immunity 2005;22:693-703.
23. Goswami R, Kaplan MH. Gcn5 is required for PU.1-dependent IL9 induction in Th9 cells. J Immunol 2012;189:3026-33.
24. Jabeen R, Goswami R, Awe O, Kulkarni A, Nguyen ET, Attenasio A, et al. Th9 cell development requires a BATF-regulated transcriptional network. J Clin Invest 2013;123:4641-53.
25. Yao W, Tepper RS, Kaplan MH. Predisposition to the development of IL9-secreting T cells in atopic infants. J Allergy Clin Immunol 2011;128:1357-60.
26. Wilhelm C, Hirota K, Stieglitz B, Van Snick J, Tolaini M, Lahl K, et al. An IL9 fate reporter demonstrates the induction of an innate IL9 response in lung inflammation. Nat Immunol 2011;12:1071-7.
27. Faulkner H, Humphreys N, Renauld JC, Van Snick J, Grencis R. Interleukin-9 is involved in host protective immunity to intestinal nematode infection. Eur J Immunol 1997;27:2536-40.
28. + T cells in malignant pleural effusion. Am J Respir Crit Care Med 2012;186:1168-79.
29. Khazaie K, Blatner NR, Khan MW, Gounari F, Gounaris E, Dennis K, et al. The significant role of mast cells in cancer. Cancer Metastasis Rev 2011;30:45-60.
30. Lv X, Wang X. The role of interleukin-9 in lymphoma. Leuk Lymphoma 2013;54:1367-72.
31. Taki S, Sato T, Ogasawara K, Fukuda T, Sato M, Hida S, et al. Multistage regulation of Th1-type immune responses by the transcription factor IRF-1. Immunity 1997;6:673-9.
32. Eyles J, Puaux AL, Wang X, Toh B, Prakash C, Hong M, et al. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest 2010;120:2030-9.
33. + T cell expansion and function. J Exp Med 2005;201:139-48.
34. + T cells. J Immunol 2005;175:755-62.
35. Petrella TM, Tozer R, Belanger K, Savage KJ, Wong R, Smylie M, et al. Interleukin-21 has activity in patients with metastatic melanoma: a phase II study. J Clin Oncol 2012;30:3396-401.
36. Lee YK, Turner H, Maynard CL, Oliver JR, Chen D, Elson CO, et al. Late developmental plasticity in the T helper 17 lineage. Immunity 2009;30:92-107.
37. Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, et al. Tumorspecific Th17-polarized cells eradicate large established melanoma. Blood 2008;112:362-73.